Skip to main content

Table 3 Comparison of demographic and clinical characteristics in patients with and without audiographically demonstrated ototoxicity

From: Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

  Ototoxicity N = 30 No ototoxicity N = 47 Univariate model Multivariate modela
OR (95%CI) P value OR (95%CI) P value
Sex, female 24 (80%) 29 (61.7%) 2.48 (0.85–7.24) 0.096 4.96 (1.24–19.87) 0.024
Age (years), median (IQR) 61 (43–65) 65 (51–72) 0.98 (0.95–1.01) 0.247 0.98 (0.94–1.02) 0.297
Race
 Caucasian 22 (73.3%) 29 (61.7%) 1.71 (0.63–4.64) 0.295   
 South Asian 1 (3.3%) 1 (2.1%) 1.59 (0.09–26.36) 0.748   
 East Asian 6 (20%) 16 (34%) 0.48 (0.16–1.42) 0.188 0.24 (0.06–0.95) 0.042
 African 1 (3.3%) 1 (2.1) 1.59 (0.09–26.36) 0.748   
Weekly dose AK per bodyweight (mg/kg/week), median (IQR)b 29 (23.7–41.3) 25.2 (21.8–29.4) 1.05 (1.00–1.10) 0.047 1.03 (0.98–1.09) 0.248
Months on AK, median (IQR) 11.5 (7–18.25) 7 (4–10) 1.04 (1.00–1.08) 0.052   
Total dose AK per bodyweight (g/kg), Median (IQR)c 1.81 (0.85–3.13) 0.74 (0.51–1.27) 1.59 (1.08–2.33) 0.018 1.62 (1.08–2.43) 0.020
Total dose AK (g), Median (IQR)d 77.3 (52.9–196.3) 41.7 (25.6–67.5) 1.01 (1.00–1.02) 0.011   
Repeated exposure to amikacin 9 (30%) 10 (21.3%) 1.59 (0.56–1.52) 0.388   
Baseline weight (kg), Median (IQR) 51.5 (41–66.5) 55 (48–64) 0.99 (0.96–1.03) 0.712   
Initial serum creatinine (umol/L), mean (SD) 66.0 (56.7–74.0) 63 (53–75) 1.01 (0.97–1.04) 0.656   
Baseline disabling hearing impairment 8 (26.7%) 24 (51.1%) 0.35 (0.13–0.94) 0.037 0.54 (0.17–1.74) 0.305
Current treatment with macrolides 29 (96.7%) 45 (95.7%) 1.23 (0.11–14.87) 0.839   
Nephrotoxicity 1 (3.6%) 4 (8.5%) 0.38 (0.04–3.58) 0.398   
  1. IQR Interquartile Range, AK Amikacin
  2. aVariables with a p-value < 0.2 in the univariate analysis, and variables considered a priori to be clinically important, were included in the multivariate model, wherein multicollinearity was explored using variance inflation factor (VIF). Months on amikacin and total dose amikacin per bodyweight both had VIFs> 10, and so were eliminated
  3. bOR represents risk associated with each increase of 1 mg/kg/week
  4. cOR represents risk associated with each increase of 1 g/kg total dose
  5. dOR represents risk associated with each increase of 1 g total dose
  6. Total dose of amikacin and months on amikacin were excluded from the multivariate analysis due to collinearity